OCTREOTIDE INJECTION SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

OCTREOTIDE (OCTREOTIDE ACETATE)

Inapatikana kutoka:

MONT-PHARMA INC

ATC kanuni:

H01CB02

INN (Jina la Kimataifa):

OCTREOTIDE

Kipimo:

100MCG

Dawa fomu:

SOLUTION

Tungo:

OCTREOTIDE (OCTREOTIDE ACETATE) 100MCG

Njia ya uendeshaji:

INTRAVENOUS

Vitengo katika mfuko:

100

Dawa ya aina:

Prescription

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0121548001; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2023-03-07

Tabia za bidhaa

1
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION
INFORMATIO N
PR OCTREOTIDE INJECTION
50 MCG / ML, 100 MCG / ML, 200 MCG / ML, 500 MCG / ML OCTREOTIDE (AS
ACETATE)
Solution for Subcutaneous injection or intravenous infusion
Synthetic Octapeptide Analogue of Somatostatin
Mont-Pharma Inc
2379 Rue Guenette
Montreal, Quebec
H4R 2E9
SUBMISSION CONTROL NUMBER: 271522
DATE OF
INITIAL AUTHORIZATION:
MAR 2, 2023
2
RECENT MAJOR LABEL CHANGES
4 DOSAGE AND ADMINISTRATION, 4.2 RECOMMENDED DOSE AND DOSAGE
ADJUSTMENT, CARCINOID TUMORS
03/2023
4 DOSAGE AND ADMINISTRATION, 4.3 RECOMMENDED DOSE AND DOSAGE
ADJUSTMENT, RECONSTITUTION, PARENTERAL PRODUCTS
03/2023
7 WARNING AND PRECAUTIONS, HEPATIC/ BILIARY / PANCREATIC
03/2023
7 WARNING AND PRECAUTIONS, MONITORING AND LABORATORY TESTS
03/2023
7 WARNING AND PRECAUTIONS, FERTILITY
03/2023
7 WARNING AND PRECAUTIONS, TERATOGENIC RISK
03/2023
7 WARNING AND PRECAUTIONS, 7.1.4 GERIATRICS
03/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
......................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................. 4
1.
INDICATIONS
.............................................................................................................................
4
1.1
Pediatrics
....................................................................................................................................
5
1.2
Geriatrics
....................................................................................................................................
5
2.
CONTRAINDICATIONS
............................................................................................................
5
4.
DOSAGE AND ADMINISTRATION
...............................